EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database

Yusuke Narita, Takashi Funatogawa, Kazuma Mii, Hiroki Adachi, Aya Tamura, Shinji Yamakido

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Yusuke Narita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Biological Products, Scleroderma, Systemic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Limited information is available on the use of biologics in patients with systemic sclerosis (SSc) or SSc-associated interstitial lung disease (SSc-ILD) in Japan. The types of biologics, treatment duration, treatment prior to biologics, concomitant treatment, and characteristics of patients receiving biologics were investigated.

Methods

We used a Japanese hospital claims database provided by Medical Data Vision Co. (2008–2021).

Results

In the database, 1186 of 34,207 SSc patients (3.5%) and 620 of 12,303 SSc-ILD patients (5.0%) received anti-interleukin-6 (anti-IL-6) drugs, anti-tumour necrosis factor (anti-TNF) drugs, abatacept, or rituximab. The most common were anti-IL-6 drugs [used in 35.5% of SSc patients and 38.5% of SSc-ILD patients (tocilizumab, 34.5% and 36.6%)], followed by anti-TNF drugs [31.3% and 26.5% (etanercept, 10.5% and 9.0%; others, <8%)], abatacept (17.5% and 20.6%), and rituximab (15.7% and 14.4%). Among SSc and SSc-ILD patients treated with anti-IL-6 drugs, anti-TNF drugs, or abatacept, the most common immunosuppressive drugs prior to initiation of biologics were methotrexate and tacrolimus. Approximately half of patients receiving anti-IL-6 drugs, anti-TNF drugs, or abatacept continued treatment beyond 1 year.

Conclusions

Our study indicates that off-label biologics have been used in a certain number of SSc or SSc-ILD patients in Japan, with tocilizumab the most common.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialBiological ProductsScleroderma, SystemicHumansRituximabAbataceptEast Asian PeopleTumor Necrosis Factor InhibitorsHospitalsLung

Stichwörter der Autor:innen

Anti-interleukin-6biologicshospital claims databaseinterstitial lung diseasesystemic sclerosis

Substanzen

RituximabAbataceptBiological ProductsTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.

Zitieren

APA

Narita, Y., Funatogawa, T., Mii, K., Adachi, H., Tamura, A., & Yamakido, S. (2023). Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database. Modern Rheumatology. https://doi.org/10.1093/mr/roac055

Vancouver

Narita Y, Funatogawa T, Mii K, Adachi H, Tamura A, Yamakido S. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database. Modern Rheumatology. 2023. doi:10.1093/mr/roac055

BibTeX
@article{Narita2023,
  author = {Narita, Yusuke and Funatogawa, Takashi and Mii, Kazuma and Adachi, Hiroki and Tamura, Aya and Yamakido, Shinji},
  title = {Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac055}
}
Kostenlos starten →